Tiziana Life Sciences #TILS – Initiates Phase 1 Clinical Trial with Orally Administered Foralumab, a Fully Human anti-CD3 monoclonal antibody, in Healthy Volunteers December 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

London/New York, 4 December 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a clinical-stage biotechnology company focused on developing innovative therapeutics for inflammatory diseases and cancers, is pleased to announce initiation of a Phase I clinical trial in healthy volunteers with a proprietary oral formulation of Foralumab encapsulated in enteric-coated capsules. The primary objective of this single ascending dose (SAD) phase 1 study, being led by Dr. Tanuja Chitnis at the Brigham and Women’s Hospital,…

Alan Green talks Santa Rally, Funds, JD Sports #JD, Tiziana Life Sciences #TILS & Itaconix #ITX on Vox Markets podcast December 3, 2019 – Posted in: Blog, Tiziana Life Sciences (TILS)

Alan Green discusses Santa Rally, funds, JD Sports #JD, Tiziana Life Sciences #TILS & Itaconix #ITX with Justin Waite on the Vox Markets podcast. The interview is 19 minutes 13 seconds in.

Tiziana Life Sciences #TILS – Issue of convertible unsecured loan notes with warrants to raise £1,434,000 November 1, 2019 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 1 November 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has raised £1,434,000 of finance by way of the issue of convertible unsecured loan notes (the “Loan Notes”), with warrants attached, for working capital purposes. The Company previously announced its intention to raise additional equity share capital by way of an…

Tiziana Life Sciences (TILS) Interim Results for the Six Months Ended 30 June 2019 September 30, 2019 – Posted in: Tiziana Life Sciences (TILS)

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need London, 30 September 2019 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), the research and clinical stage biotechnology company focussing on proprietary drug candidates to treat cancer and autoimmune diseases, today announces its interim results for the six months ended 30 June 2019. Highlights during the period: RESEARCH & DEVELOPMENT CLINICAL PROGRAMMES Foralumab TZLS-401 Foralumab…

Tiziana Life Sciences #TILS Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers September 16, 2019 – Posted in: Blog, Tiziana Life Sciences (TILS)

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers. A breakthrough approach for treatment of autoimmune and inflammatory diseases London, 16…

Tiziana Life Sciences #TILS Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers September 10, 2019 – Posted in: Tiziana Life Sciences (TILS)

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Tiziana Life Sciences plc Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers New…

Tiziana Life Sci PLC (TILS) Teplizumab Article July 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes; Findings may have the potential to expand therapeutic benefits of Tiziana’s Foralumab, the only known fully human anti-CD3 mAb Independent third party Phase 2 results show Teplizumab, a mouse derived humanized anti-CD3 monoclonal antibody (mAb) significantly slowed progression of Type 1 diabetes in high risk population Tiziana Life…

Tiziana Life Sci PLC (TILS) Change of Adviser – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces the appointment of Shore Capital Stockbrokers Limited as Broker, with immediate effect. This follows the acquisition of Stockdale Securities Limited by Shore Capital Markets Limited. For further enquiries: Tiziana Life Sciences plc +44 (0)20 7493 2853 Gabriele Cerrone, Chairman and founder …

Tiziana Life Sciences plc – PDMR dealings June 25, 2019 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 25 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 24 June 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought ordinary shares of nominal value 3p each in the capital of the Company, as set out below, following prior consultation with the Takeover Panel in relation to Note…

Tiziana Life Sci Plc (TILS) Article on Clinical Activity of OKT3 June 24, 2019 – Posted in: Tiziana Life Sciences (TILS)

Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monoclonal Antibody Platform Third party research conducted by leading U.S. institutions to be published in a peer reviewed journal Crohn’s & Colitis 360 shows orally administered anti-CD3 resulted in anti-inflammatory gene expression with no serious treatment related adverse events up to a dose of 1 mg of OKT3 Tiziana’s…